Blocking an age-linked protein restored cartilage in mice


Researchers found that existing cartilage cells changed their activity after treatment. Human surgical tissue also responded, but the approach has not been shown to work in patients.
Blocking a protein called 15-PGDH restored cartilage in older mice and reduced osteoarthritis development after knee injuries, according to a Stanford Medicine-led study reported by ScienceDaily. The researchers found that existing cartilage cells changed their gene activity toward making healthy joint cartilage, without recruiting stem cells. The study was published in Science.
That finding addresses a central difficulty in osteoarthritis: the smooth cartilage covering joint surfaces normally has little ability to repair itself. As it breaks down, joints become painful, swollen and harder to move. Current treatments mainly manage symptoms, and severe damage can require joint replacement; no drug reliably slows or reverses the disease itself.
15-PGDH is an enzyme that breaks down a molecule called prostaglandin E2. Earlier work by the researchers linked blocking this enzyme, or raising prostaglandin E2 levels, to regeneration in other mouse tissues. They wanted to find out whether the same biological process could help cartilage damaged by age or injury.
The researchers found roughly twice as much 15-PGDH in knee cartilage from old mice as from young mice. The older animals also had thinner, less functional cartilage. Helen Blau, a senior author of the study, noted that prostaglandin E2 is associated with inflammation and pain, but said the experiments indicated that small increases within normal biological levels could promote regeneration.
The team gave older mice a drug that inhibits, or blocks the activity of, 15-PGDH. In one experiment, abdominal injections were intended to let the drug act throughout the body. In another, the drug went directly into the knee joint. ScienceDaily reports that both approaches thickened cartilage across the joint surface.
The cells produced hyaline cartilage—the smooth, low-friction tissue also called articular cartilage in joints—rather than fibrocartilage, a tougher type less suited to that surface. The distinction matters because osteoarthritis commonly damages articular cartilage.
To understand the change, the researchers examined cartilage cells, called chondrocytes. Before treatment, older cells showed more activity in genes associated with inflammation and conversion of hyaline cartilage into bone, and less activity in genes involved in normal cartilage development. Treatment changed the proportions of cell groups defined by their gene activity.
| Cell group | Before | After |
|---|---|---|
| Produced 15-PGDH; expressed genes associated with cartilage breakdown | 8% | 3% |
| Did not produce 15-PGDH; expressed genes linked to fibrocartilage formation | 16% | 8% |
| Did not produce 15-PGDH; expressed genes linked to hyaline-cartilage formation and maintenance of the molecular network surrounding cartilage cells | 22% | 42% |
That network surrounding cartilage cells, called the extracellular matrix, consists of proteins and other molecules that give cartilage its structure and help it withstand pressure. The researchers interpreted the shifts as existing cells moving toward a younger, cartilage-producing state, rather than stem or progenitor cells supplying new cartilage.
In a separate experiment involving knee injuries similar to anterior cruciate ligament (ACL) tears in people, mice received the inhibitor twice a week for four weeks after injury. The researchers reported reduced osteoarthritis development. Mice given a control drug developed osteoarthritis within four weeks and had twice the 15-PGDH levels of uninjured animals.
Treated mice also moved more normally and put more weight on the paw attached to the injured leg than untreated mice did. These were functional observations in mice, not evidence that the treatment improves movement or pain in people.
The researchers also treated cartilage removed from people with osteoarthritis during total knee replacement surgery. After one week, the tissue contained fewer chondrocytes expressing 15-PGDH. Compared with untreated tissue, genes associated with cartilage breakdown and fibrocartilage were less active, and the samples began regenerating articular cartilage, ScienceDaily reports.
A response in removed tissue does not establish that a drug can regrow cartilage or prevent osteoarthritis in patients. Whether the approach can reduce the need for joint replacement remains unresolved.
The researchers have financial interests in the approach. Blau, fellow senior author Nidhi Bhutani and other coauthors are inventors on Stanford University patent applications concerning 15-PGDH inhibition for cartilage and tissue rejuvenation. Those applications are licensed to Epirium Bio. Blau is a cofounder of Myoforte/Epirium and holds equity and stock options in the company.
An oral 15-PGDH inhibitor has entered clinical testing for muscle weakness, not cartilage regeneration. Blau said phase 1 trials found it safe and active in healthy volunteers. That statement does not establish long-term safety or effectiveness as a cartilage treatment.
Blau expressed hope that a cartilage-regeneration trial would follow. Trials specifically testing that use in patients are needed to determine whether the experimental repair can become a safe and effective treatment.

A comparison of 123 species offers clues to how birds produce loud calls, but not why those calls evolved.
2 min

The rover’s project scientist says the layer differs in colour and tilt from its surroundings. Ancient volcanic ash is one possible origin, not a confirmed finding.

NASA plans to join the rocket’s central stage to the boosters for a propellant-loading test and crew emergency-exit rehearsal, without Orion or the upper adapters.
3 min
2 min